[go: up one dir, main page]

ES2161288T3 - Comprimido revestido con polimero que comprende amoxicilina y clavulanato. - Google Patents

Comprimido revestido con polimero que comprende amoxicilina y clavulanato.

Info

Publication number
ES2161288T3
ES2161288T3 ES95917937T ES95917937T ES2161288T3 ES 2161288 T3 ES2161288 T3 ES 2161288T3 ES 95917937 T ES95917937 T ES 95917937T ES 95917937 T ES95917937 T ES 95917937T ES 2161288 T3 ES2161288 T3 ES 2161288T3
Authority
ES
Spain
Prior art keywords
amoxycline
clavulanate
polymer
compressed closed
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917937T
Other languages
English (en)
Inventor
C P Smithkline Beecham Conley
N P Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10754044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2161288(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2161288T3 publication Critical patent/ES2161288T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

MEDICAMENTO EN FORMA DE COMPRIMIDO PARA SER ADMINISTRADO ORALMENTE EN EL TRATAMIENTO DE LAS INFECCIONES BACTERIANAS, EL COMPRIMIDO CONTIENE UNA MEZCLA COMPACTA DE 750-950 MG DE AMOXICILINA Y UNA CANTIDAD DE CLAVULANATO EN UN PORCENTAJE DE PESO AMOXICILINA-CLAVULANATO ENTRE 6:1 A 8:1 INCLUSIVE, Y QUE TIENE UNA PELICULA DE COBERTURA DE POLIMEROS QUE SE PUEDE APLICAR MEDIANTE TECNICAS DE REVESTIMIENTO ACUOSAS.
ES95917937T 1994-04-23 1995-04-19 Comprimido revestido con polimero que comprende amoxicilina y clavulanato. Expired - Lifetime ES2161288T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408117A GB9408117D0 (en) 1994-04-23 1994-04-23 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2161288T3 true ES2161288T3 (es) 2001-12-01

Family

ID=10754044

Family Applications (4)

Application Number Title Priority Date Filing Date
ES95917937T Expired - Lifetime ES2161288T3 (es) 1994-04-23 1995-04-19 Comprimido revestido con polimero que comprende amoxicilina y clavulanato.
ES00204182T Expired - Lifetime ES2182754T3 (es) 1994-04-23 1995-04-19 Procedimiento para preparar comprimidos revestidos con polimero, que comprenden amoxicilina y clavulanato revestidos con un revestimiento polimero acuoso formador de pelicula.
ES96202848T Expired - Lifetime ES2152485T3 (es) 1994-04-23 1995-04-19 Procedimiento para preparar comprimidos que contienen amoxicilina y clavulanato recubiertos de una pelicula polimerica acuosa.
ES99200891T Expired - Lifetime ES2180251T3 (es) 1994-04-23 1995-04-19 Comprimido revestido con polimero, que contiene amoxicilina y clavulanato.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES00204182T Expired - Lifetime ES2182754T3 (es) 1994-04-23 1995-04-19 Procedimiento para preparar comprimidos revestidos con polimero, que comprenden amoxicilina y clavulanato revestidos con un revestimiento polimero acuoso formador de pelicula.
ES96202848T Expired - Lifetime ES2152485T3 (es) 1994-04-23 1995-04-19 Procedimiento para preparar comprimidos que contienen amoxicilina y clavulanato recubiertos de una pelicula polimerica acuosa.
ES99200891T Expired - Lifetime ES2180251T3 (es) 1994-04-23 1995-04-19 Comprimido revestido con polimero, que contiene amoxicilina y clavulanato.

Country Status (35)

Country Link
US (1) US6051255A (es)
EP (5) EP0761218B1 (es)
JP (1) JP3622975B2 (es)
CN (1) CN1134258C (es)
AP (2) AP564A (es)
AT (6) ATE196845T1 (es)
AU (1) AU684949B2 (es)
BG (1) BG62842B1 (es)
BR (1) BR9507502A (es)
CA (1) CA2188496A1 (es)
CZ (2) CZ294168B6 (es)
DE (5) DE29522153U1 (es)
DK (4) DK1093813T3 (es)
DZ (1) DZ1876A1 (es)
ES (4) ES2161288T3 (es)
FI (1) FI964249L (es)
GB (1) GB9408117D0 (es)
GR (2) GR3035031T3 (es)
HK (1) HK1050992A1 (es)
HU (1) HU228399B1 (es)
IL (1) IL113433A (es)
MA (1) MA23528A1 (es)
MY (1) MY115351A (es)
NO (1) NO310703B1 (es)
NZ (1) NZ285080A (es)
OA (1) OA10377A (es)
PL (1) PL316966A1 (es)
PT (4) PT758235E (es)
RO (1) RO116997B1 (es)
RU (1) RU2152213C1 (es)
SA (1) SA95160343B1 (es)
SI (1) SI0758235T1 (es)
SK (1) SK282594B6 (es)
WO (1) WO1995028927A1 (es)
ZA (1) ZA953236B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
NZ337247A (en) * 1995-09-07 2001-05-25 Smithkline Beecham Corp Pharmaceutical tablet formulation comprising 875mg amoxycillin
AT403375B (de) * 1995-11-15 1998-01-26 Biochemie Gmbh Verfahren zur fällung von alkalisalzen der clavulansäure
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
WO1998034598A2 (en) * 1997-02-07 1998-08-13 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
CA2280857A1 (en) * 1997-02-14 1998-08-20 Smithkline Beecham Laboratoires Pharmaceutiques Pharmaceutical formulations comprising amoxocyllin and clavulanate
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
AU9540898A (en) * 1997-08-29 1999-03-22 Dsm N.V. Granules free of excipients
US6395298B1 (en) 1997-10-31 2002-05-28 Pharmacia Corporation Gellan gum tablet coating
CN1209099C (zh) 1999-04-01 2005-07-06 Dsm公司 结晶化附聚物
EP1044680B1 (en) * 1999-04-13 2003-06-11 Beecham Pharmaceuticals (Pte) Limited Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
AU2001292185A1 (en) * 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
MXPA03008997A (es) * 2001-04-10 2004-02-12 Sun Pharmaceutical Ind Ltd Composicion de liberacion por impulso temporizado.
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
AU2003210925A1 (en) * 2002-02-07 2003-09-02 Rutgers, The State University Antibiotic polymers
GB0203528D0 (en) * 2002-02-14 2002-04-03 Glaxo Group Ltd Process and composition
ES2263949T3 (es) * 2002-02-14 2006-12-16 Glaxo Group Limited Composicion farmaceutica que comprende n-((1-n-butil-4-piperidinil)mentil)-3,4-dihidro-2h-(1,3)oxazino (3,2-aindol-10-carboxamida o una sal de la misma y procedimiento para su preparacon que comprende granulacion por via seca.
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
KR100638315B1 (ko) * 2004-07-23 2006-10-25 주식회사 대웅제약 다중 필름 코팅된 코어층을 갖는 클라불라네이트 및아목시실린-함유 유핵정
KR101318032B1 (ko) 2005-05-20 2013-10-14 다이이찌 산쿄 가부시키가이샤 필름 코팅 제제
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CL2008003230A1 (es) * 2007-11-01 2009-11-27 Sanofi Aventis Healthcare Pty Ltd Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta.
SI2477611T1 (sl) * 2009-09-18 2017-07-31 Sanofi Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1508977A (en) 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
US4098897A (en) * 1975-04-14 1978-07-04 Beecham Group Limited Anti bacterial agents
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
EP0080862B1 (en) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
EP1044680B1 (en) * 1999-04-13 2003-06-11 Beecham Pharmaceuticals (Pte) Limited Novel method of treatment using a high dosage regimen of amoxycillin and potassium clavulanate
AU2001292185A1 (en) * 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin

Also Published As

Publication number Publication date
DE69528204D1 (de) 2002-10-17
EP0978276B1 (en) 2002-09-11
DE29522153U1 (de) 2000-04-06
FI964249A7 (fi) 1996-10-22
HK1027024A1 (en) 2001-01-05
DE69519093T2 (de) 2001-07-19
WO1995028927A1 (en) 1995-11-02
JPH09512027A (ja) 1997-12-02
ZA953236B (en) 1995-12-27
AT5349U1 (de) 2002-06-25
DE69528608T2 (de) 2003-06-26
EP0978276A3 (en) 2000-04-12
ATE226074T1 (de) 2002-11-15
DE69528204T2 (de) 2003-08-07
CN1149829A (zh) 1997-05-14
IL113433A (en) 2003-06-24
DK1093813T3 (da) 2003-02-17
NZ285080A (en) 1998-05-27
EP1243267A2 (en) 2002-09-25
CZ309096A3 (en) 1997-04-16
EP1243267A3 (en) 2002-10-30
HK1009936A1 (en) 1999-06-11
BG100933A (en) 1997-07-31
DK0758235T3 (da) 2001-10-29
HK1036404A1 (en) 2002-01-04
OA10377A (en) 2001-11-21
AT5350U1 (de) 2002-06-25
IL113433A0 (en) 1995-07-31
HUT76335A (en) 1997-08-28
DE69521799D1 (de) 2001-08-23
NO964488D0 (no) 1996-10-22
ATE196845T1 (de) 2000-10-15
AP9600868A0 (en) 1996-10-31
PT758235E (pt) 2001-10-31
GR3035031T3 (en) 2001-03-30
SK135496A3 (en) 1997-05-07
DE69521799T2 (de) 2002-06-13
SA95160343B1 (ar) 2005-05-04
US6051255A (en) 2000-04-18
AP564A (en) 1996-11-21
EP0758235A1 (en) 1997-02-19
GR3036844T3 (en) 2002-01-31
HU9602922D0 (en) 1996-12-30
CA2188496A1 (en) 1995-11-02
CN1134258C (zh) 2004-01-14
JP3622975B2 (ja) 2005-02-23
EP1093813A3 (en) 2001-05-30
EP1093813B1 (en) 2002-10-16
ATE223706T1 (de) 2002-09-15
PL316966A1 (en) 1997-03-03
PT761218E (pt) 2001-03-30
HK1021860A1 (en) 2000-07-07
CZ11376U1 (cs) 2001-07-12
AU684949B2 (en) 1998-01-08
DZ1876A1 (fr) 2002-02-17
MY115351A (en) 2003-05-31
ES2182754T3 (es) 2003-03-16
EP0758235B1 (en) 2001-07-18
ATE203161T1 (de) 2001-08-15
DK0978276T3 (da) 2003-01-20
FI964249A0 (fi) 1996-10-22
RO116997B1 (ro) 2001-09-28
BG62842B1 (bg) 2000-09-29
EP0978276A2 (en) 2000-02-09
CZ294168B6 (cs) 2004-10-13
BR9507502A (pt) 1997-09-02
GB9408117D0 (en) 1994-06-15
FI964249L (fi) 1996-10-22
MA23528A1 (fr) 1995-12-31
HK1050992A1 (en) 2003-07-18
ES2180251T3 (es) 2003-02-01
DE69519093D1 (de) 2000-11-16
PT978276E (pt) 2003-01-31
ES2152485T3 (es) 2001-02-01
SK282594B6 (sk) 2002-10-08
PT1093813E (pt) 2003-02-28
SI0758235T1 (en) 2001-10-31
EP0761218B1 (en) 2000-10-11
NO310703B1 (no) 2001-08-20
HU228399B1 (en) 2013-03-28
NO964488L (no) 1996-12-17
DK0761218T3 (da) 2000-12-18
EP0761218A1 (en) 1997-03-12
AU2406895A (en) 1995-11-16
AP9500733A0 (en) 1995-04-30
RU2152213C1 (ru) 2000-07-10
EP1093813A2 (en) 2001-04-25
DE69528608D1 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
ES2161288T3 (es) Comprimido revestido con polimero que comprende amoxicilina y clavulanato.
ES2162922T3 (es) Composicion para administracion colonica de medicamentos.
NO981746L (no) Utlevering av biologisk aktive polypeptider
ES2174928T3 (es) Metodo para incrementar la diodisponibilidad de composiciones farmaceuticas orales.
ES2170223T3 (es) Composicion farmaceutica que contiene hidratos de carbonato de lantano seleccionados.
MY115662A (en) Novel compounds with analgesic effect
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
MY119403A (en) Novel compounds with analgesic effect.
MY132705A (en) Novel compounds with analgesic effect
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
YU15591A (sh) Novi potisni plinovi njihova upotreba u proizvodnji lekova
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
ES2160821T3 (es) Uso de una composicion que comprende amoxicilina y acido clavulanico para la produccion de un medicamento para el tratamiento de infecciones bacterianas en pacientes pediatricos.
DE69311541D1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
BR9709316A (pt) Composição farmacêutica para administração tópica no tratamento da vaginite
AR016683A1 (es) Composicion de suministro de droga solida, anhidra, proceso y uso de una pluralidad de particulas inorganicas porosas compuestas de hidroxipatita ceramicapara su preparacion.
DE69414857D1 (de) Präparat gegen haarausfall und brüchiche nägel
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
CO4600680A1 (es) Procedimientos para la prevencion de la degradacion de la proteina c
CO4370015A1 (es) Formulacion farmaceutica comprendiendo amoxicilina y potasio de clavulanato

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 758235

Country of ref document: ES